Why—and When—to Use a CDMO

What is a CDMO? This article answers when and why to use a Contract Development and Manufacturing Organization (CDMO), and it is the first part of our “Best Practices in the CDMO Selection Process” series.

Blog
Published on:
August 25, 2022

Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons, including:

  • limited internal know-how and capacity to manufacture API according to Good Manufacturing Practice (GMP), or
  • to reduce costs and timelines.

In this article, we will explore three common reasons why a company might consider engaging a CDMO.

Resource optimization

Early clinical development naturally leads to a fast cycling of projects as candidate molecules are identified and prioritized. Providing staff and capital required for this fluctuation in demand is at the discretion of the company. If a company does invest capital and internal resources to expand its manufacturing capability, it’s best to keep those assets active to offset their high cost.

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy.
Greater technical expertise and robust infrastructure

Small virtual biotech companies and early-stage clinical companies might have limited internal capabilities and the technical expertise required to manufacture an API. Engaging a CDMO with applicable existing infrastructure and expertise can benefit the company financially while also improving overall product quality and timelines.

Cost reduction

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy. Initially, a company needs to ensure it’s utilizing its current internal resources to the maximum and only then identify what should be outsourced to a CDMO thus cutting unnecessary spending. More importantly, a carefully planned CDMO selection process can help to identify a CDMO offering the best overall value to the company. While such an identification, evaluation and selection process is not trivial, overall savings can be substantial if the entire process is carried out well.

If you are deciding to outsource your manufacturing or simply looking to obtain insight into the overall CDMO landscape in order to identify the right CDMO for your project, we are here to assist. Our expert team has been helping companies choose the right CDMO for more than a decade.

Related news

Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
Events May 16, 2023
PSI 2023 Conference
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease UK
Events May 15, 2023
World Orphan Drug Congress USA
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease
Events May 15, 2023
BIO International Convention
We are excited to share that we will be attending the BIO International Convention in Boston. This leading industry event attracts biotechnology and pharma leaders for one week of intensive(...)
Biotech Pharma
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.